Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
CRS d.o.o. is an EU-based CRO located in Ljubljana, Slovenia. Founded in 2005, it focuses on early-stage clinical research and Phase I clinical unit services. According to its website, the company has more than 20 years of Phase I–IV clinical development experience and operates as a regional Phase I clinic in Slovenia. Its clients are mainly pharmaceutical and biotech sponsors looking to conduct clinical trials under the EU regulatory framework.
CRS is not a traditional SaaS software provider; its core offering is clinical research outsourcing. Its services cover regulatory and study start-up, CTA and ethics submissions, feasibility assessment, site selection, pharmacovigilance, regulatory affairs, project management, clinical monitoring, quality assurance, data management, and statistics. For early-phase trials, it supports first-in-human studies, Phase I single and multiple ascending dose studies, BA/BE, PK/PD, bridging studies, and Phase I–IIa designs. In terms of facilities, the website states that it has two coordination units, 72+ beds, an in-house pharmacy, IMP handling, intensive PK sampling, hospital access, and emergency coverage.
The website does not disclose standard packages, pricing, payment methods, or service levels. It only provides a Request For Proposal entry point, indicating that its business model is likely project-based with customized quotations. This is fairly common for clinical research services, but before procurement, it is still necessary to further confirm the quotation scope, enrollment timeline, data delivery standards, and boundaries of quality responsibility.
Its strengths include its EU location, alignment with ICH-GCP and EU/EMA requirements, dedicated Phase I facilities, healthy volunteer recruitment capabilities, and a relatively complete CRO service chain from regulatory start-up to data statistics. Its collaboration with the University Medical Centre and the University of Ljubljana also strengthens its medical and operational support. The limitations are that the website does not demonstrate SaaS platform capabilities, third-party system integrations, APIs, permission management, data security certifications, or technical details related to GDPR. If users are looking for eClinical software or an enterprise-grade clinical data platform, the available information is clearly insufficient.
It is suitable for pharmaceutical companies, biotech firms, and generic drug developers looking to conduct early human trials, BA/BE, PK/PD, or bridging studies in the EU, especially projects that require a regional CRO and an inpatient Phase I unit. It is not suitable for companies simply looking for cloud-based CTMS, EDC, eTMF, or pharmacovigilance SaaS.
The scraped text does not provide information on access performance from mainland China, so it is currently rated as unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on crs.si official site.
crs.si is an Slovenia Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach crs.si directly.